Ambarish Kunwar

Prof. Ambarish Kunwar

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2010 in Cell
Verified
Journal Article
Closed access
RMRichard J. McKenney
Richard J. McKenney
MVMichael D. Vershinin
Michael D. Vershinin
AKAmbarish Kunwar
Ambarish Kunwar
RVRichard B. Vallee
Richard B. Vallee
SGSteven P. Gross
Steven P. Gross

14 November 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
AKAmbarish Kunwar
Ambarish Kunwar
STSuvranta K. Tripathy
Suvranta K. Tripathy
JXJing Xu
Jing Xu
MMMichelle K. Mattson
Michelle K. Mattson
PAPreetha Anand
Preetha Anand
SGSteven P. Gross
Steven P. Gross
Intracellular transport via the microtubule motors kinesin and dynein plays an important role in maintaining cell structure and function. Often, multiple kinesin or dynein motors move the same cargo. Their collective function depends critically on the single motors’ detachment kinetics under load, which we experimentally measure here. This experimental constraint—combined with other experimentally determined parameters—is then incorporated into theoretical stochastic and mean-field models. Comparison of modeling results and in vitro data shows good agreement for the stochastic, but not mean-field, model. Many cargos in vivo move bidirectionally, frequently reversing course. Because both kinesin and dynein are present on the cargos, one popular hypothesis explaining the frequent reversals is that the opposite-polarity motors engage in unregulated stochastic tugs-of-war. Then, the cargos’ motion can be explained entirely by the outcome of these opposite-motor competitions. Here, we use fully calibrated stochastic and mean-field models to test the tug-of-war hypothesis. Neither model agrees well with our in vivo data, suggesting that, in addition to inevitable tugs-of-war between opposite motors, there is an additional level of regulation not included in the models.

1 August 2008 in Current Biology
Verified
Journal Article
Closed access
AKAmbarish Kunwar
Ambarish Kunwar
MVMichael D. Vershinin
Michael D. Vershinin
JXJing Xu
Jing Xu
SGSteven P. Gross
Steven P. Gross

10 February 2010 in Physical Biology
Verified
Journal Article
Closed access
AKAmbarish Kunwar
Ambarish Kunwar
AMAlexander Mogilner
Alexander Mogilner

1 November 2013 in Trends in Cell Biology
Verified
Journal Article
Closed access
RMRoop Mallik
Roop Mallik
ARArpan K. Rai
Arpan K. Rai
PBPradeep Barak
Pradeep Barak
ARAshim Rai
Ashim Rai
AKAmbarish Kunwar
Ambarish Kunwar

4 April 2016 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
Rajan Kumar PandeyRajan Kumar Pandey
Rajan Kumar Pandey
Bajarang Vasant KumbharBajarang Vasant Kumbhar
Bajarang Vasant Kumbhar
SSShubham Srivastava
Shubham Srivastava
RMRuchi Malik
Ruchi Malik
SSShyam Sundar
Shyam Sundar
VPVijay kumar Kumar Prajapati
Vijay kumar Kumar Prajapati
Visceral leishmaniasis affects people from 70 countries worldwide, mostly from Indian, African and south American continent. The increasing resistance to antimonial, miltefosine and frequent toxicity of amphotericin B drives an urgent need to develop an antileishmanial drug with excellent efficacy and safety profile. In this study we have docked series of febrifugine analogues (n = 8813) against trypanothione reductase in three sequential docking modes. Extra precision docking resulted into 108 ligands showing better docking score as compared to two reference ligand. Furthermore, 108 febrifugine analogues and reference inhibitor clomipramine were subjected to ADMET, QikProp and molecular mechanics, the generalized born model and solvent accessibility study to ensure the toxicity caused by compounds and binding-free energy, respectively. Two best ligands (FFG7 and FFG2) qualifying above screening parameters were further subjected to molecular dynamics simulation. Conducting these studies, here we confirmed that 6-chloro-3-[3-(3-hydroxy-2-piperidyl)-2-oxo-propyl]-7-(4-pyridyl) quinazolin-4-one can be potential drug candidate to fight against Leishmania donovani parasites.